Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770105 | 1.00 | CTSK (0.55) | CTSKCTSS | |
| SCHEMBL8089276 | 1.00 | CTSK (0.55) | CTSKCTSS | |
| SCHEMBL24177101 | 0.95 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL5487452 | 0.94 | CTSK (0.49) | CTSKCTSS | |
| SCHEMBL5487455 | 0.94 | CTSK (0.49) | CTSKCTSS | |
| SCHEMBL5492762 | 0.94 | CTSK (0.49) | CTSKCTSS | |
| SCHEMBL4785473 | 0.94 | CTSK (0.49) | CTSKCTSS | |
| SCHEMBL628886 | 0.90 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL5129984 | 0.90 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL628900 | 0.90 | CTSK (0.50) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-3759075-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-3931183-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | VENTHERA, INC. | 2024-03-21 | — | — | US | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| CN-114008024-A | Compounds having iron death inducing activity and methods of using the same | 费罗治疗公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
| EP-1008592-B1 | Cyclic amide derivatives which inhibit cathepsin K | SEIKAGAKU KOGYO CO LTD (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1619189-A1 | N-(3-acyl-2-hydroxyalkyl) cycloalkyl amide derivatives | SEIKAGAKU CORPORATION (JP) | 2006-01-25 | — | — | EP | disclosed |
| EP-1616867-A1 | Hydroxycarboxylic acid derivatives | SEIKAGAKU CORPORATION (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-1616859-A1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU CORPORATION (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-0812835-B1 | OPTICALLY ACTIVE THIAZOLIDINONE DERIVATIVES | SANKYO CO (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-6117870-A | USEFUL AS THERAPEUTIC DRUG OR PREVENTIVE DRUG OF ARTHRITIS AND RHEUMATISM DUE TO INCREASE OF BONE RESORPTION IN ADDITION TO BONE DISEASES SUCH AS OSTEOPOROSIS, HYPERCALCEMIA, AND PAGET'S DISEASE | FUJIREBIO KABUSHIKI KAISHA (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1008592-A2 | Cyclic amide derivatives which inhibit cathepsin K | Fujirebio Kabushiki Kaisha (JP) | 2000-06-14 | — | — | EP | disclosed |
| US-5925658-A | PREVENTING OR TREATING ANGINA PECTORIS | SANKYO COMPANY, LIMITED (JP) | 1999-07-20 | — | — | US | disclosed |
| US-5891898-A | ANTIULCER AGENT | SANKYO COMPANY, LIMITED (JP) | 1999-04-06 | — | — | US | disclosed |
| EP-0812835-A1 | OPTICALLY ACTIVE THIAZOLIDINONE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | CTSK 820/4885CTSS 898/4885 |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | CTSK 820/4885CTSS 898/4885 |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | CTSK 820/4885CTSS 898/4885 |
| US-11040964-B2 | Compounds and methods of use | AIFM2, GPX4, GPX1 | CTSK 820/4885CTSS 898/4885 |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | CTSK 686/4885CTSS 619/4885 |
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, SLC40A1, GPX4 | CTSK 632/4885CTSS 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.